GATIFLOXACIN MESYLATE manufacturers
- GATIFLOXACIN MESYLATE
-
- $0.00 / 25kg
-
2025-04-14
- CAS:316819-28-0
- Min. Order: 25kg
- Purity: 99.0%
- Supply Ability: 10tons
- Gatifloxacin (mesylate)
-
- $0.00 / 1g
-
2024-11-19
- CAS:316819-28-0
- Min. Order: 1g
- Purity: 98% HPLC
- Supply Ability: 100kg
|
| | GATIFLOXACIN MESYLATE Basic information |
| Product Name: | GATIFLOXACIN MESYLATE | | Synonyms: | GATIFLOXACIN MESYLATE;3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-Methoxy-7-(3-Methyl-1-piperazinyl)-4-oxo-, MonoMethanesulfonate (9CI);AM 1155 mesylate;AM 1155 MESYLATE;BMS 206584-01 MESYLATE;PD 135432 MESYLATE;BMS 206584-01 mesylate;Gatifloxacin mesylate
(AM 1155 mesylate;PD 135432 mesylate);GATIFLOXACIN MESYLATE USP/EP/BP | | CAS: | 316819-28-0 | | MF: | C19H22FN3O4.CH4O3S | | MW: | 471.503 | | EINECS: | | | Product Categories: | | | Mol File: | 316819-28-0.mol |  |
| | GATIFLOXACIN MESYLATE Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | Powder |
| | GATIFLOXACIN MESYLATE Usage And Synthesis |
| Uses | Gatifloxacin mesylate is a fourth generation fluoroquinolone antibiotic with broad-spectrum antibacterial activity. It is able to inhibit bacterial type II topoisomerase (IC50 = 13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA rotamase (IC50 = 0.109 μg/ml). It can be used to treat bacterial conjunctivitis in vivo, and its injection can treat acute urinary tract infections with efficacy comparable to levofloxacin hydrochloride injection[1]. | | References | [1] L. DENG. Observation on the curative effect of gatifloxacin mesylate injection in the treatment of acute urinary tract infections[J]. 国际医药卫生导报, 2009. DOI:10.3760/CMA.J.ISSN.1007-1245.2009.05.025. |
| | GATIFLOXACIN MESYLATE Preparation Products And Raw materials |
|